Sulforafan alfadex

Drug Profile

Sulforafan alfadex

Alternative Names: SFX-01; Stabilised sulforaphane; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadex

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evgen Pharma; Lalilab; PharmAgra Labs
  • Developer Evgen Pharma
  • Class Antineoplastics; Chemopreventatives; Phytotherapies
  • Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Signal transduction pathway modulators; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Subarachnoid haemorrhage
  • Preclinical Multiple sclerosis
  • No development reported Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Breast-cancer in United Kingdom (PO)
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top